You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Bacteriostatic Sodium Chloride 0.9% In Plastic Container patents expire, and when can generic versions of Bacteriostatic Sodium Chloride 0.9% In Plastic Container launch?

Bacteriostatic Sodium Chloride 0.9% In Plastic Container is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, and Hospira. and is included in three NDAs.

The generic ingredient in BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is sodium chloride. There are one thousand four hundred and seventy-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the sodium chloride profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER?
  • What are the global sales for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER?
  • What is Average Wholesale Price for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER?
Summary for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Drug patent expirations by year for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Recent Clinical Trials for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alfonso X El Sabio UniversityPhase 1
Assistance Publique Hopitaux De MarseillePhase 4
Sham Sunder KakarPhase 1/Phase 2

See all BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER clinical trials

Pharmacology for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

US Patents and Regulatory Information for BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER sodium chloride SOLUTION;INJECTION 088909-002 May 15, 1985 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hospira BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER sodium chloride SOLUTION;INJECTION 018800-003 Oct 29, 1982 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER sodium chloride SOLUTION;INJECTION 088911-001 Feb 7, 1985 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Abraxis Pharm BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER sodium chloride SOLUTION;INJECTION 088909-001 Feb 7, 1985 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER sodium chloride SOLUTION;INJECTION 088911-002 May 17, 1985 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.